Skip to content

Temperature Recording in Lungs of Volunteers With and Without Pulmonary Diseases

Temperature Recording in Lungs of Volunteers With and Without Pulmonary Diseases

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05344300
Acronym
TEMP-REC-LUNG
Enrollment
10
Registered
2022-04-25
Start date
2022-09-01
Completion date
2025-09-30
Last updated
2023-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiectasis, Heat, Heat Exposure, Temperature Change, Body

Brief summary

The purpose of the project is to estimate the air temperature in the lungs after a change from room temperature (25℃) to an environment with a constant temperature of 88-92℃ in resp. lung-healthy persons and persons with bronchiectasis.

Detailed description

Heat is a widely available therapeutic modality and is often used for recovery after physical activity and pain treatment, and sauna bathing is a form of whole body thermotherapy ranging from 80-100 ℃ and low humidity of 10-20%. The heat load in a sauna has been shown to activate several beneficial physiological effects, and no adverse effects on the lungs have been demonstrated. It is unknown how much the air temperature in the lower respiratory tract (bronchial tree) in humans rises to under surroundings of 88-92℃. This is an observational, clinical trial investigating the changes in air temperature at different bronchial segments in both lungs under surroundings of 88-92℃ resp. in lung-healthy persons and persons with bronchiectasis.

Interventions

OTHERTemperature-measurement in lungs under sauna bath

Through a bronchoscopy procedure under an 88-92℃ environment, the air temperature is measured in the 1st, 2nd and 3rd bronchial segment, at 4th and 5th bronchial segment and at 6th-10th bronchial segment in resp. the right and left lung. The temperature is measured at time: 0 seconds (s), 15 s, 30 s, 45 s, 60 s, 75 s, 90 s, 105 s, 120 s, 135 s and 150 s.

Sponsors

Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Lung-healthy group: Inclusion criteria: * Age ≥ 18 years * Competent and capable * Forced expiratory volume in the first second (FEV1)\>1,0 L * Does not suffer from bronchiectasis, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, sarcoidosis, active lung infection (past 30 days) or lung cancer

Exclusion criteria

* Allergy to lidocaine and/or midazolam * Contraindications to bronchoscopy\* * Previous severe laryngospasm (intubation requiring) * Pregnancy/breastfeeding * Severe linguistic problems or inability to give informed consent * Severe mental illness that is not controlled with medication. NB: Patients with controlled mental illness can be included and will be asked on an equal footing as others Bronchiectasis group: Inclusion criteria: * Age ≥ 18 years * Competent and capable * FEV1\>1,0 L * Have diagnosed bronchiectasis \[radiology verified and evaluated by pulmonary specialist\]

Design outcomes

Primary

MeasureTime frameDescription
Changes in air temperature1 dayChanges in air temperature (under 88-92℃ surroundings) measured in both lungs at 1st, 2nd and 3rd bronchial segment, at 4th and 5th bronchial segment and at 6th-10th. bronchial segment at times 0 s, 15 s, 30 s, 45 s, 60 s, 75 s, 90 s, 105 s, 120 s, 135 s, and 150 s.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026